A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer

References

• Sunakawa Y, Izawa N, Mizukami T, et al. Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy. Onco Targets Ther. 2017;10:4599–4605.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Uetake H, Fujita N, et al. TAS-102 safety in metastatic colorectal cancer: results from the first postmarketing surveillance study. Clin Colorectal Cancer. 2016;15:205–211.
   PubMed Web of Science ®Google Scholar
• Mulet N, Matos I, Noguerido A, et al. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer. Expert Opin Pharmacother. 2018;19:623–629.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13:993–1001.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–1919.
   PubMed Web of Science ®Google Scholar
• Xu J, Kim TW, Shen L, et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncol. 2018;36:350–358.
   PubMed Web of Science ®Google Scholar
• Streiner DL, Norman GR. Efficacy and effectiveness trials. Cumunity Oncol. 2009;6:472–474.
   Google Scholar
• Cohen AT, Goto S, Schreiber K, et al. Why do we need observational studies of everyday patients in the real-life setting? Eur Heart J Suppl. 2015;17:D2–D8.
   Web of Science ®Google Scholar
• Joanna Briggs Institute. JBI Critical Appraisal Checklist for Cohort Studies. Avaiilable at http://joannabriggs.org/research/critical-appraisal-tools.html
   Google Scholar
• Arita S, Shirakawa T, Matsushita Y, et al. Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. Anticancer Res. 2016;36:1959–1966.
   PubMed Web of Science ®Google Scholar
• Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5:52.
   PubMedGoogle Scholar
• Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152.
   PubMed Web of Science ®Google Scholar
• Bland JM, Kerry SM. Statistics notes. Weighted comparison of means. Br Med J. 1998;316:129.
   PubMed Web of Science ®Google Scholar
• Ota T, Tsukuda H, Hasegawa Y, et al. Treatment of TAS-102 in patients with metastatic colorectal cancer. Ann Oncol. 2016;27.
   Google Scholar
• Masuishi T, Taniguchi H, Hamauchi S, et al. Regorafenib versus trifluridine/tipiracil for refractory metastatic colorectal cancer: a retrospective comparison. Clin Colorectal Cancer. 2017;16:e15–e22.
   PubMed Web of Science ®Google Scholar
• Moriwaki T, Fukuoka S, Taniguchi H, et al. Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese society for cancer of the colon and rectum multicenter observational study. Oncologist. 2018;23:7–15.
   PubMed Web of Science ®Google Scholar
• Kwakman JJM, Vink G, Vestjens JH, et al. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. Int J Clin Oncol. 2018;23:482–489.
   PubMed Web of Science ®Google Scholar
• Cremolini C, Rossini D, Martinelli E, et al. Trifluridine/tipiracil (TAS-102) in refractory metastatic colorectal cancer: a multicenter register in the frame of the Italian compassionate use program. Oncologist. 2018;23:1–10.
   PubMed Web of Science ®Google Scholar
• Sueda T, Sakai D, Kudo T, et al. Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies. Anticancer Res. 2016;36:4299–4306.
   PubMed Web of Science ®Google Scholar
• Kotani D, Shitara K, Kawazoe A, et al. Safety and efficacy of trifluridine/tipiracil monotherapy in clinical practice for patients with metastatic colorectal cancer: experience at a single institution. Clin Colorectal Cancer. 2016;15:e109–e115.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
   PubMed Web of Science ®Google Scholar
• Favoriti P, Carbone G, Greco M, et al. Worldwide burden of colorectal cancer: a review. Updates Surg. 2016;68:7–11.
   PubMed Web of Science ®Google Scholar
• Mercier J, Voutsadakis IA. A systematic review and meta-analysis of retrospective series of regorafenib for treatment of metastatic colorectal cancer. Anticancer Res. 2017;37:5925–5934.
   PubMed Web of Science ®Google Scholar
• Gomez SL, O’Malley CD, Stroup A, et al. Longitudinal, population-based study of racial/ethnic differences in colorectal cancer survival: impact of neighborhood socioeconomic status, treatment and comorbidity. BMC Cancer. 2007;7:193.
   PubMed Web of Science ®Google Scholar
• Cicero G, De Luca R, Dieli F. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer. Onco Targets Ther. 2018;11:3059–3063.
   PubMed Web of Science ®Google Scholar
• Panageas KS, Ben-Porat L, Dickler MN, et al. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2007;99:428–432.
   PubMed Web of Science ®Google Scholar
• Michiels S, Piedbois P, Burdett S, et al. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care. 2005;21:119–125.
   PubMed Web of Science ®Google Scholar
• Huang B, Kuan P-F. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point. Pharm Stat. 2018;17:202–213.
   PubMed Web of Science ®Google Scholar
• Trinquart L, Jacot J, Conner SC, et al. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. J Clin Oncol. 2016;34:1813–1819.
   PubMed Web of Science ®Google Scholar
• A’Hern RP. Cancer biology and survival analysis in cancer trials: restricted mean survival time analysis versus hazard ratios. Clin Oncol. 2018;30:e75–e80.
   Web of Science ®Google Scholar
• Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18:1221–1237.
   PubMed Web of Science ®Google Scholar
• Bullement A, Underhill S, Fougeray R, et al. Cost-effectiveness of trifluridine/tipiracil for previously treated metastatic colorectal cancer in England and Wales. Clin Colorectal Cancer. 2018;17:e143–e151.
   PubMed Web of Science ®Google Scholar
• Haynes B. Can it work? Does it work? Is it worth it? The testing of healthcareinterventions is evolving. Br Med J. 1999;319:652–653.
   PubMed Web of Science ®Google Scholar
• Singal AG, Higgins PDR, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5:e45.
   PubMed Web of Science ®Google Scholar
• Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet. 2005;365:82–93.
   PubMed Web of Science ®Google Scholar
• Abrahao ABK, Ko Y-J, Berry S, et al. A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis. Clin Colorectal Cancer. 2018;17:113–120.
   PubMed Web of Science ®Google Scholar
• van der Velden DL, Opdam FL, Opdam FL. TAS-102 and the quest for predictive biomarkers. ESMO Open. 2017;2:e000263.
   PubMed Web of Science ®Google Scholar
• Peeters M, Cervantes A, Moreno VS, et al. Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. Future Oncol. 2018;14:1629–1645.
   PubMed Web of Science ®Google Scholar